Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 13/20 | 0.38 |
| ▸ | PPARG | P37231 | 12/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6549641 | 0.99 | SLC6A4 (0.38) | SLC6A4PPARAPPARGNPC1RAB9A | |
| SCHEMBL6549805 | 0.98 | SLC6A4 (0.36) | SLC6A4PPARAPPARGNPC1RAB9A | |
| SCHEMBL6549954 | 0.94 | NPC1 (0.39) | SLC6A4PPARAPPARGNPC1RAB9A | |
| SCHEMBL6548572 | 0.93 | NPC1 (0.39) | SLC6A4PPARAPPARGNPC1RAB9A | |
| SCHEMBL6548630 | 0.92 | PPARA (0.46) | PPARAPPARGNPC1RAB9AKDM4E | |
| SCHEMBL6549849 | 0.92 | NPC1 (0.37) | SLC6A4PPARAPPARGNPC1RAB9A | |
| SCHEMBL6548877 | 0.91 | PPARA (0.45) | PPARAPPARGNPC1RAB9AKDM4E | |
| SCHEMBL6549804 | 0.90 | PPARA (0.43) | PPARAPPARGNPC1RAB9AHTT | |
| SCHEMBL6547187 | 0.90 | PPARA (0.47) | SLC6A4PPARAPPARG | |
| SCHEMBL6547702 | 0.89 | NPC1 (0.39) | SLC6A4PPARAPPARGNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975586-B1 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | SLC6A4 4778/4885PPARA 2987/4885PPARG 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.